<DOC>
	<DOCNO>NCT02532114</DOCNO>
	<brief_summary>This phase I trial study side effect best dose niclosamide give together enzalutamide treat patient castration resistant prostate cancer spread primary site place body . Androgens testosterone cause growth prostate cancer cell . Drugs like enzalutamide block androgen drive tumor growth ; however , androgen receptor splice variant present , drug may effective . Niclosamide may decrease amount androgen receptor splice variant present within tumor cell , thus promote anti-tumor effect enzalutamide . Giving niclosamide together enzalutamide may better treatment prostate cancer .</brief_summary>
	<brief_title>Niclosamide Enzalutamide Treating Patients With Castration-Resistant , Metastatic Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety tolerability three-times-daily ( TID ) oral niclosamide combine enzalutamide men castration-resistant prostate cancer ( CRPC ) progress abiraterone ( abiraterone acetate ) . SECONDARY OBJECTIVES : I . Determine effect niclosamide plus enzalutamide androgen receptor splice variant ( AR-V ) expression determine quantitative reverse-transcriptase-polymerase-chain-reaction ( qRT-PCR ) . II . Determine pharmacokinetic profile three-times-daily ( TID ) oral niclosamide men castration-resistant prostate cancer ( CRPC ) progress abiraterone . III . Determine prostate specific antigen ( PSA ) response rate ( i.e . proportion subject &gt; = 50 % decline PSA pre-study baseline ) 28-days niclosamide plus enzalutamide . IV . Determine effect niclosamide plus enzalutamide protein expression transcriptional program circulate tumor cell . OUTLINE : This dose-escalation study niclosamide . Patients receive niclosamide orally ( PO ) TID enzalutamide PO daily . Treatment continue 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow day 58 88 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Niclosamide</mesh_term>
	<criteria>Have sign inform consent document indicate subject understands purpose procedure require study willing participate study Be willing/able adhere prohibition restriction specify protocol Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Documented histologically confirm adenocarcinoma prostate Patient must evidence castration resistant prostate cancer evidence confirm rise PSA ( per Prostate Cancer Working Group 2 [ PCWG2 ] criterion ) castrate serum testosterone level ( i.e . = &lt; 50 mg/dL ) Patient must eligible treatment enzalutamide Patient must previously progress abiraterone ( either PCWG2 criterion Response Evaluation Criteria Solid Tumors [ RECIST ] criterion ) Documented metastatic disease bone scan , compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) Have know allergy , hypersensitivity , intolerance enzalutamide niclosamide excipients Ongoing systemic therapy ( gonadotropin release hormone [ GnRH ] agonist/antagonist ) prostate cancer include , limited : Cytochrome P450 , family 17 ( CYP17 ) inhibitor ( e.g . ketoconazole , abiraterone ) Antiandrogens ( e.g . bicalutamide , nilutamide ) Second generation antiandrogens ( e.g . ARN509 ) Immunotherapy ( e.g . sipuleucelT , ipilimumab ) Chemotherapy ( e.g . docetaxel , cabazitaxel ) Radiopharmaceutical therapy ( e.g . radium223 , strontium89 , samarium153 ) Have condition , opinion investigator , would compromise wellbeing subject study prevent subject meeting performing study requirement Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol followup schedule Severe hepatic impairment ( ChildPugh class C ) Severe renal impairment ( creatinine clearance = &lt; 30 ml/min ) History prior seizure Central nervous system metastases Symptomatic patient , opinion investigator , may benefit docetaxelbased chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>